NCT04547166View on ClinicalTrials.gov

A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

568

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

September 24, 2025

Study Completion Date

December 30, 2026

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

HLX10

a single fixed dose of 300 mg, intravenous infusion (IV), every 3 weeks (Day 1 of each cycle \[D1\]), non-reducible.

DRUG

HLX04、

7.5mg/kg, IV, every 3 weeks (D1 of each cycle), non-reducible.

Trial Locations (5)

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

510075

RECRUITING

Center for Cancer Prevention and Treatment of Sun Yat-sen University, Guangzhou

Unknown

RECRUITING

Linyi Cancer Hospital, Linyi

RECRUITING

Fudan University Affiliated Oncology Hospital, Shanghai

NOT_YET_RECRUITING

National Cancer Center, Kashiwa

All Listed Sponsors
lead

Shanghai Henlius Biotech

INDUSTRY